![]() The company also announced that Beverly Huss, co-founder and CEO at Pagonia Medical, a temperature management and tissue preservation company, has joined its Board of Directors. “There is a very large unmet clinical need for patients with HFrEF and we are confident thatĪncora Heart’s unique therapeutic approach is well positioned to play a key role in helping these people obtain the treatment that they need,” said Andrew Midler, founder of Savitr Capital. Approximately 50 percent of people who develop heart failure die within five years of diagnosis. About half of HF patients have heart failure with a reduced ejection fraction (HFrEF) and an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency. 1 Heart failure patients suffer from debilitating symptoms including persistent exhaustion, trouble breathing, confusion and loss of memory. adults live with heart failure, a condition in which the heart’s muscles weaken and lose their ability to pump enough oxygen-rich blood to the body. “We are grateful to our new and returning investors for their support for our vision to provide a promising new treatment option for people suffering from heart failure.”Īn estimated 6.5 million U.S. “Ancora Heart is at an exciting stage as we continue with our pivotal clinical trial to support our PMA submission to the FDA, and this investment will help us prepare for potential launch and subsequent commercialization,” said Jeff Closs, president and CEO of Ancora Heart. The funds will be used to accelerate the CORCINCH-HF pivotal clinical study of the AccuCinch ® Ventricular Restoration System, designed to treat patients who have symptomatic heart failure with reduced ejection fraction (HFrEF).Īs the only completely transcatheter procedure to treat the enlarged left ventricle, the AccuCinch System is a fundamentally different and innovative device-based therapy designed to improve the structure and function of the heart and help bring relief to HF patients who remain symptomatic despite current guideline-directed medical care. Sands Capital, Sio Capital and an undisclosed strategic investor joined all existing investors in this financing. , a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing. ancoraDocs eliminates hours of manual data entry while improving productivity and accuracy.Santa Clara, Calif.– J– Ancora Heart, Inc. Our solutions are capable of identifying and capturing data from nearly any business document allowing us to add value to nearly any organization. Other hidden costs stemming from data inaccuracies, manual document sorting, filing, and more are also eliminated with automation. ![]() ancoraDocs removes that burden by automating data entry. ![]() When employees are keying data, they are not focused on their core duties-and that hampers a company’s ability to accomplish work efficiently. However, it extracts a real price in terms of lost productivity and increased labor costs. Manual data entry creates an often-hidden cost, as the task of keying data is usually dispersed across departments and employees. Through ancoraDocs we are enabling companies around the world to dramatically reduce the costs and inefficiencies of manual data entry-as well as other manual processes. The premise behind ancora Software is to finally bring to market an advanced data capture solution that does not come with the typical complexity and over engineered features and functionality that has resulted in difficult to use, difficult to implement, difficult to support and over priced Capture software. ![]()
0 Comments
Leave a Reply. |